A decorative graphic consisting of several small, dark blue dots of varying sizes scattered across the white background.

DaVolterra


Florence SEJOURNE

17 Mars 2014



Da Volterra's Mission


Biotech Company focused on developing,
up to Proof of Concept in man,
innovative therapeutic and preventive products to combat life-
threatening
multi-resistant bacterial infections
and their consequences



Resistant E.coli to Fluoroquinolones in Europe (2002-2011)


2002

2011



Overall trends of prevalence of resistant Bacteria in Chinese tertiary Hospitals (2000-2011):

Up to 70%



Xiao, PLOS Medicine, 1 Nov 2013 Issue 11

IMPENEM-RESISTANT Acinetobacter baumannii



IMPENEM-RESISTANT Acinetobacter baumannii



Estimated minimum number of illnesses and deaths caused by antibiotic resistance*:

At least **2,049,442** illnesses,

23,000 deaths

ANTIBIOTIC RESISTANCE THREATS in the United States, 2013



U.S. Department of
Health and Human Services
Centers for Disease
Control and Prevention

CLOSTRIDIUM DIFFICILE



250,000
INFECTIONS PER YEAR



14,000
DEATHS



\$1,000,000,000

IN EXCESS MEDICAL COSTS PER YEAR



THREAT LEVEL

URGENT



This bacteria is an immediate public health threat
that requires urgent and aggressive action.

A Dramatic R&D Pipeline Gap




Figure 1. New systemic antibacterial agents approved by the US Food and Drug Administration per 5-year period, through 2012. Modified from Spellberg 2004 [23].


Da Volterra in Brief

- ❑ Labs and headquarters downtown Paris
Scientific founder Prof Antoine Andremont, AP-HP, Diderot Univ.
20 people - 75% PharmD PhD MD Eng - 40 advisors
- ❑ Focused on developing novel products for a major worldwide unmet healthcare need: the rise of antimicrobial resistance
Disruptive strategies supported by microbiology, critical care, and infectious diseases Key Opinion leaders
1 product in Phase I clinical development
- ❑ Records of successful execution: Clinical-stage company in the antibacterial field with preclinical PoC data, Solid Patent Portfolio, Family office + Non-dilutive Grant funding, Several Risk-sharing Partnerships signed


DAV132

Product Rationale

During all antibiotic treatments, a fraction of the antibiotics reaches the colon and impacts the intestinal microbiota, promoting emergence & spread of resistant bacteria, and triggering *C.difficile* infections



DAV132 Protects the Commensal Flora during Atb Treatments, Preventing *C.difficile* Infections



Biotechnology

Fever rising

15 Feb 2014

Biology is complex. Drugs have a habit of being too toxic or not working as well as they should...

Indeed, creating new drugs through biotechnology is at the risky end of a business in which superhuman stamina and bottomless pockets are minimum requirements.

Overcome these obstacles, however, and the returns can be fabulous!




DaVolterra

172 rue de Charonne - 75 011 Paris, France
Tel: +33 1 58 39 32 20 - Fax: +33 1 58 39 32 21

<http://www.davolterra.com>
contact@davolterra.com